SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility due to renewed global trade tensions, specifically concerning former President Trump's comments on Greenland and potential tariffs on European allies. The community is sharply divided, with bears anticipating a deeper market correction driven by geopolitical concerns and bond market stability, while bulls are aggressively buying dips, confident in a swift rebound and a potential policy reversal. This dynamic creates significant swings as participants debate the market's underlying strength amidst uncertainty.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending after reporting positive Phase 1 clinical trial data for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile, particularly in treatment-resistant patients. The news has ignited significant community discussion around a potential short squeeze and sustained bullish momentum, with many anticipating future partnerships or a buyout. This early success in a large therapeutic market is generating considerable interest in the stock's long-term potential.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a key licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community views as a significant validation for the platform and a catalyst for potential future collaborations. Many are actively discussing the stock's high short interest, anticipating a substantial market move as the short thesis weakens. Despite this positive development, debates continue around management's overall strategy to maximize shareholder value and secure additional deals for its pipeline assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its earnings report, with community sentiment sharply divided on whether subscriber growth and ad-tier performance will spark a rally or a significant drop. The recent all-cash offer for Warner Bros. Discovery assets is a key discussion point, seen by some as a strategic play to secure the deal and by others as a potentially costly move impacting future debt. Traders are also noting the stock's oversold conditions, with some positioning for a rebound despite broader market uncertainties.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is currently at the center of a volatile discussion driven by recent tariff threats from the administration over geopolitical disputes and a criminal probe involving the Federal Reserve Chair. The community is sharply divided, with many anticipating significant market downturns due to potential trade wars and threats to Fed independence, while others view these developments as opportunities to 'buy the dip'. This confluence of political and economic uncertainties is creating intense debate and driving broad market anxiety.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150.</li><li>Alongside the investment, David E. Lazar has been named Co-Chief Executive Officer and Chairman of the Board.</li><li>The company plans to use the funds raised from the offering to support daily operations, cover severance, and manage general corporate needs.&nbsp;</li></ul>Indaptus Therapeutics Inc. (INDP) announced on Monday that it has secured a $6 million investment through the sale of non-voting convertible preferred stock to investor David E. Lazar.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INDP">Indaptus’ stock</a> traded over 12% higher. However, on Stocktwits, retail sentiment around the stock changed to ‘bearish’ from ‘extremely bearish’ territory the previous day amid ‘extremely low’ message volume levels.&nbsp;<h2 class="st-heading-2">Transaction Details&nbsp;</h2>The investment, finalized on December 23, includes 300,000 Series AA preferred shares and 700,000 Series AAA preferred shares. Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150, pending stockholder approval expected in the first-quarter (Q1) 2026.<blockquote>"In making this significant investment in Indaptus, I look forward to continuing to evaluate the company’s lead product candidate while actively exploring strategic opportunities to drive value for our stockholders.”-David E. Lazar, Investor</blockquote>Alongside the investment, David E. Lazar has been named Co-Chief Executive Officer and Chairman of the Board. Once stockholder approval is received, Lazar can nominate up to three additional directors.<h2 class="st-heading-2">Strategic Implications</h2>The company plans to use the funds raised from the offering to support daily operations, cover severance, manage general corporate and working capital needs, and pay offering-related costs, including securing stockholder approval.Indaptus develops Decoy, a patented, antigen-agnostic immunotherapy using attenuated Gram-negative bacteria to activate innate and adaptive immune responses. Preclinical studies show tumor and viral eradication, enhanced by combinations with checkpoint inhibitors or chemotherapy.Indaptus’ Decoy platform activates and matures multiple human immune cells in vitro, exhibits low toxicity upon intravenous administration, and demonstrates promising single-agent activity against chronic hepatitis B and HIV in preclinical studies.INDP stock has declined by over 90% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soft-bank-acquires-digital-bridge-for-4-billion-to-scale-ai-infrastructure/cL75v6iREx9">SoftBank Acquires DigitalBridge For $4 Billion To Scale AI Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did INDP Stock Gain 12% Today?

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 

Equity

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 


What Does the Market Think About Indaptus Therapeutics Inc?

Biotech Stocks To Keep An Eye On - December 24th

Abivax, Indaptus Therapeutics, Danaher, Vertex Pharmaceuticals, Moderna, argenex, and Amicus Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

INDP
Indaptus Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest INDP News

INDPIndaptus Therapeutics Inc